Encapsulation of Demeclocycline in Cubosomes for the Study of α-Synuclein Amyloid Aggregation

Vol 4, 2026 - 345893
Abstract
Favorite this paper
How to cite this paper?
Abstract

Parkinson’s disease is a neurodegenerative disorder characterized by the accumulation of intracellular inclusions enriched in amyloid fibrils formed by the protein α-synuclein, therefore, the aggregation of α-synuclein into fibrillar species is considered an important target for the development of therapeutic strategies. Previous studies have shown that tetracycline-family antibiotics, particularly doxycycline, can interfere with α-synuclein aggregation and modify the formation of amyloid species, however, the low aqueous solubility and hydrophobic character of some compounds in this class may limit their application and bioavailability. In this context, nanostructured lipid carriers such as cubosomes represent a promising drug delivery system for the encapsulation of hydrophobic molecules. This project aims to investigate whether the encapsulation of demeclocycline, a tetracycline-family compound, in cubosomes can provide a suitable delivery system while preserving its potential anti-amyloid activity against α-synuclein aggregation. Initially, cubosomes will be prepared using a bottom-up method based on phytantriol and Pluronic F127 and subsequently characterized. Demeclocycline will then be incorporated into the lipid nanostructures, and the physicochemical properties and stability of the resulting system will be investigated.  The interaction between α-synuclein, demeclocycline and the cubosomes will subsequently be studied in order to evaluate possible changes in the protein aggregation process. Small-angle X-ray scattering (SAXS), fluorescence correlation spectroscopy (FCS) and Dynamic Light Scattering (DLS) will be employed to characterize structural and dynamic changes in the system and to investigate the formation and evolution of aggregated species. Comparisons between free demeclocycline and the encapsulated compound will allow the assessment of whether cubosome-based delivery affects the interaction of the drug with α-synuclein and its ability to interfere with amyloid formation. The study may contribute to a better understanding of the interactions between lipid nanostructures, therapeutic compounds and amyloidogenic proteins, while exploring a potential drug repurposing strategy for compounds of the tetracycline family. More broadly, the proposed approach may contribute to the development of nanostructured delivery systems for hydrophobic compounds with potential applications in neurodegenerative diseases.

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 Instituto de Física da Universidade de São Paulo
  • 2 Universidade de São Paulo
Track
  • 4. Bioengineering and Biomaterial
Keywords
α-Synuclein
Amyloid fibrils
Demeclocycline
Cubosomes
Drug repurposing